{"drugResultsOutput": {"Filters": {"@total": "14", "Filter": [{"@total": "97", "@label": "Technologies", "@name": "technologies", "FilterOption": [{"@id": "761", "@count": "135", "@label": "Biological therapeutic"}, {"@id": "762", "@count": "108", "@label": "Small molecule therapeutic"}, {"@id": "766", "@count": "60", "@label": "Parenteral formulation unspecified"}, {"@id": "648", "@count": "50", "@label": "Intravenous formulation"}, {"@id": "740", "@count": "29", "@label": "Infusion"}, {"@id": "62", "@count": "28", "@label": "Virus recombinant"}, {"@id": "585", "@count": "27", "@label": "Oral formulation"}, {"@id": "599", "@count": "25", "@label": "Nanoparticle formulation injectable"}, {"@id": "85", "@count": "19", "@label": "Protein recombinant"}, {"@id": "651", "@count": "16", "@label": "Intramuscular formulation"}, {"@id": "103", "@count": "15", "@label": "Oligonucleotide"}, {"@id": "142", "@count": "13", "@label": "Liposome formulation"}, {"@id": "1668", "@count": "12", "@label": "Nanoparticle formulation"}, {"@id": "569", "@count": "11", "@label": "Oligonucleotide antisense"}, {"@id": "647", "@count": "10", "@label": "Subcutaneous formulation"}, {"@id": "595", "@count": "9", "@label": "Tablet formulation"}, {"@id": "166", "@count": "8", "@label": "Chimeric monoclonal antibody"}, {"@id": "80", "@count": "8", "@label": "Peptide"}, {"@id": "169", "@count": "8", "@label": "Monoclonal antibody humanized"}, {"@id": "603", "@count": "8", "@label": "Systemic formulation unspecified"}, {"@id": "102", "@count": "7", "@label": "Nucleotide and derivatives"}, {"@id": "168", "@count": "7", "@label": "Monoclonal antibody human"}, {"@id": "573", "@count": "7", "@label": "Immunoglobulin-G"}, {"@id": "962", "@count": "7", "@label": "Biosimilar product"}, {"@id": "1652", "@count": "6", "@label": "Prodrug"}, {"@id": "84", "@count": "6", "@label": "Protein fusion"}, {"@id": "598", "@count": "6", "@label": "Liposome formulation injectable"}, {"@id": "589", "@count": "6", "@label": "Sustained release formulation"}, {"@id": "611", "@count": "5", "@label": "Dermatological formulation"}, {"@id": "596", "@count": "5", "@label": "Injectable formulation"}, {"@id": "175", "@count": "4", "@label": "Drug combination"}, {"@id": "558", "@count": "4", "@label": "Transdermal formulation"}, {"@id": "67", "@count": "4", "@label": "Antigen"}, {"@id": "160", "@count": "4", "@label": "Vector expression"}, {"@id": "51", "@count": "3", "@label": "Monoclonal antibody"}, {"@id": "171", "@count": "3", "@label": "Monoclonal antibody conjugated"}, {"@id": "1", "@count": "3", "@label": "Antibody"}, {"@id": "641", "@count": "3", "@label": "Controlled release formulation"}, {"@id": "112", "@count": "3", "@label": "DNA technology"}, {"@id": "167", "@count": "3", "@label": "Monoclonal antibody murine"}, {"@id": "1647", "@count": "3", "@label": "Natural product"}, {"@id": "180", "@count": "3", "@label": "Antibody fragment"}, {"@id": "851", "@count": "3", "@label": "Intradermal formulation"}, {"@id": "586", "@count": "3", "@label": "Capsule formulation"}, {"@id": "348", "@count": "3", "@label": "PEGylated formulation"}, {"@id": "605", "@count": "2", "@label": "Nasal systemic formulation"}, {"@id": "745", "@count": "2", "@label": "Suspension"}, {"@id": "582", "@count": "2", "@label": "Antibody polyclonal"}, {"@id": "593", "@count": "2", "@label": "Oral liquid formulation"}, {"@id": "594", "@count": "2", "@label": "Oral suspension formulation"}, {"@id": "207", "@count": "2", "@label": "Protein conjugated"}, {"@id": "617", "@count": "2", "@label": "Aerosol formulation inhalant"}, {"@id": "743", "@count": "2", "@label": "Granule"}, {"@id": "623", "@count": "2", "@label": "Vaginal formulation"}, {"@id": "751", "@count": "2", "@label": "Film coating"}, {"@id": "616", "@count": "2", "@label": "Inhalant formulation"}, {"@id": "55", "@count": "2", "@label": "Transgenic animal"}, {"@id": "612", "@count": "2", "@label": "Emulsion dermatological"}, {"@id": "349", "@count": "2", "@label": "Lipid"}, {"@id": "753", "@count": "2", "@label": "Microparticle formulation"}, {"@id": "775", "@count": "2", "@label": "Dermatological gel formulation"}, {"@id": "287", "@count": "1", "@label": "Transdermal high velocity particle formulation"}, {"@id": "630", "@count": "1", "@label": "Stereochemistry"}, {"@id": "746", "@count": "1", "@label": "Solution"}, {"@id": "606", "@count": "1", "@label": "Transmucosal formulation"}, {"@id": "117", "@count": "1", "@label": "RNA technology"}, {"@id": "93", "@count": "1", "@label": "Toxin"}, {"@id": "1653", "@count": "1", "@label": "Tumor antigen"}, {"@id": "771", "@count": "1", "@label": "Rectal gel formulation"}, {"@id": "901", "@count": "1", "@label": "Recombinant enzyme"}, {"@id": "1655", "@count": "1", "@label": "Tumor antigen therapeutic"}, {"@id": "66", "@count": "1", "@label": "Antibiotic"}, {"@id": "768", "@count": "1", "@label": "Vaginal gel formulation"}, {"@id": "898", "@count": "1", "@label": "Formulation powder"}, {"@id": "750", "@count": "1", "@label": "Freeze drying"}, {"@id": "74", "@count": "1", "@label": "Glycoprotein"}, {"@id": "280", "@count": "1", "@label": "Immunization passive"}, {"@id": "4", "@count": "1", "@label": "Immunoglobulin"}, {"@id": "1669", "@count": "1", "@label": "Emulsion formulation"}, {"@id": "597", "@count": "1", "@label": "Injectable emulsion"}, {"@id": "652", "@count": "1", "@label": "Intra-articular formulation"}, {"@id": "654", "@count": "1", "@label": "Intrathecal formulation"}, {"@id": "347", "@count": "1", "@label": "Intratumoral formulation"}, {"@id": "852", "@count": "1", "@label": "Intravesical formulation"}, {"@id": "864", "@count": "1", "@label": "Mesenchymal stem cell therapy"}, {"@id": "583", "@count": "1", "@label": "Crystalline form"}, {"@id": "1667", "@count": "1", "@label": "Nanoparticle formulation dermatological"}, {"@id": "591", "@count": "1", "@label": "Nanoparticle formulation oral"}, {"@id": "222", "@count": "1", "@label": "Cell targeting"}, {"@id": "1651", "@count": "1", "@label": "Blood constituents"}, {"@id": "159", "@count": "1", "@label": "Oligosaccharide"}, {"@id": "620", "@count": "1", "@label": "Ophthalmic formulation"}, {"@id": "659", "@count": "1", "@label": "Ophthalmic liquid formulation"}, {"@id": "660", "@count": "1", "@label": "Oral sustained release formulation"}, {"@id": "856", "@count": "1", "@label": "Autologous stem cell therapy"}, {"@id": "215", "@count": "1", "@label": "Antigen presentation system"}, {"@id": "756", "@count": "1", "@label": "Pharmaceutical carrier"}]}, {"@total": "100", "@label": "Primary Indications", "@name": "indicationsPrimary", "FilterOption": [{"@id": "1049", "@count": "31", "@label": "Ebola virus infection"}, {"@id": "651", "@count": "26", "@label": "Cancer"}, {"@id": "191", "@count": "17", "@label": "Influenza virus infection"}, {"@id": "152", "@count": "13", "@label": "Hepatitis B virus infection"}, {"@id": "1048", "@count": "11", "@label": "Marburg virus infection"}, {"@id": "158", "@count": "10", "@label": "HIV infection"}, {"@id": "153", "@count": "10", "@label": "Hepatitis C virus infection"}, {"@id": "344", "@count": "9", "@label": "Viral infection"}, {"@id": "49", "@count": "8", "@label": "Breast tumor"}, {"@id": "205", "@count": "6", "@label": "Melanoma"}, {"@id": "1262", "@count": "6", "@label": "Non-small-cell lung cancer"}, {"@id": "127", "@count": "5", "@label": "Stomach tumor"}, {"@id": "291", "@count": "5", "@label": "Rheumatoid arthritis"}, {"@id": "799", "@count": "5", "@label": "Ovary tumor"}, {"@id": "725", "@count": "4", "@label": "Solid tumor"}, {"@id": "2637", "@count": "4", "@label": "Non-alcoholic steatohepatitis"}, {"@id": "84", "@count": "4", "@label": "Crohns disease"}, {"@id": "623", "@count": "4", "@label": "Head and neck tumor"}, {"@id": "276", "@count": "4", "@label": "Prostate tumor"}, {"@id": "285", "@count": "3", "@label": "Rabies virus infection"}, {"@id": "3246", "@count": "3", "@label": "Hormone refractory prostate cancer"}, {"@id": "281", "@count": "3", "@label": "Psoriasis"}, {"@id": "1261", "@count": "3", "@label": "Small-cell lung cancer"}, {"@id": "3665", "@count": "3", "@label": "Metastatic non small cell lung cancer"}, {"@id": "1290", "@count": "3", "@label": "Filovirus infection"}, {"@id": "1011", "@count": "3", "@label": "Esophagus tumor"}, {"@id": "746", "@count": "3", "@label": "Infectious disease"}, {"@id": "3657", "@count": "3", "@label": "Metastatic breast cancer"}, {"@id": "337", "@count": "3", "@label": "Ulcerative colitis"}, {"@id": "1270", "@count": "3", "@label": "Variola virus infection"}, {"@id": "3669", "@count": "2", "@label": "Metastatic pancreas cancer"}, {"@id": "3234", "@count": "2", "@label": "Polyomavirus infection"}, {"@id": "3399", "@count": "2", "@label": "Familial amyloid neuropathy"}, {"@id": "1828", "@count": "2", "@label": "Multiple myeloma"}, {"@id": "2454", "@count": "2", "@label": "Glioblastoma"}, {"@id": "1108", "@count": "2", "@label": "Glioma"}, {"@id": "2318", "@count": "2", "@label": "Liver fibrosis"}, {"@id": "1297", "@count": "2", "@label": "Paroxysmal nocturnal hemoglobinuria"}, {"@id": "201", "@count": "2", "@label": "Liver disease"}, {"@id": "396", "@count": "2", "@label": "Papillomavirus infection"}, {"@id": "224", "@count": "2", "@label": "Myocardial infarction"}, {"@id": "249", "@count": "2", "@label": "Pancreas tumor"}, {"@id": "2316", "@count": "2", "@label": "Neuromyelitis optica"}, {"@id": "2989", "@count": "2", "@label": "Kidney transplant rejection"}, {"@id": "1296", "@count": "2", "@label": "Keratoconjunctivitis"}, {"@id": "319", "@count": "2", "@label": "Non-Hodgkin lymphoma"}, {"@id": "362", "@count": "2", "@label": "Hepatitis D virus infection"}, {"@id": "156", "@count": "2", "@label": "Hereditary angioedema"}, {"@id": "3456", "@count": "2", "@label": "Influenza virus B infection"}, {"@id": "157", "@count": "2", "@label": "Herpes simplex virus infection"}, {"@id": "161", "@count": "2", "@label": "Hodgkins disease"}, {"@id": "3455", "@count": "2", "@label": "Influenza virus A infection"}, {"@id": "188", "@count": "2", "@label": "Inflammatory disease"}, {"@id": "837", "@count": "2", "@label": "Non-insulin dependent diabetes"}, {"@id": "174", "@count": "2", "@label": "Hypercholesterolemia"}, {"@id": "466", "@count": "2", "@label": "Vaccinia virus infection"}, {"@id": "398", "@count": "2", "@label": "Ankylosing spondylitis"}, {"@id": "89", "@count": "2", "@label": "Cytomegalovirus infection"}, {"@id": "1781", "@count": "2", "@label": "Psoriatic arthritis"}, {"@id": "14", "@count": "2", "@label": "Alzheimers disease"}, {"@id": "97", "@count": "2", "@label": "Diabetes mellitus"}, {"@id": "2477", "@count": "2", "@label": "Primary sclerosing cholangitis"}, {"@id": "3257", "@count": "2", "@label": "Stage IV melanoma"}, {"@id": "65", "@count": "2", "@label": "Stroke"}, {"@id": "7", "@count": "2", "@label": "Adenovirus infection"}, {"@id": "1735", "@count": "2", "@label": "Chronic myelocytic leukemia"}, {"@id": "1995", "@count": "2", "@label": "Primary biliary cirrhosis"}, {"@id": "3046", "@count": "2", "@label": "Chikungunya virus infection"}, {"@id": "1731", "@count": "2", "@label": "Acute myelogenous leukemia"}, {"@id": "2020", "@count": "2", "@label": "Duchenne dystrophy"}, {"@id": "1287", "@count": "1", "@label": "Venezuelan equine encephalitis virus infection"}, {"@id": "1128", "@count": "1", "@label": "Neuroendocrine tumor"}, {"@id": "1295", "@count": "1", "@label": "Neuropathic pain"}, {"@id": "678", "@count": "1", "@label": "Neuropathy"}, {"@id": "384", "@count": "1", "@label": "Vaccination"}, {"@id": "3788", "@count": "1", "@label": "Uveal melanoma"}, {"@id": "427", "@count": "1", "@label": "Uterine cervix tumor"}, {"@id": "1584", "@count": "1", "@label": "Unstable angina"}, {"@id": "3503", "@count": "1", "@label": "Viral hemorrhagic fever"}, {"@id": "671", "@count": "1", "@label": "Myocardial disease"}, {"@id": "273", "@count": "1", "@label": "Myeloproliferative disorder"}, {"@id": "1286", "@count": "1", "@label": "Western equine encephalitis virus infection"}, {"@id": "1272", "@count": "1", "@label": "Myelodysplastic syndrome"}, {"@id": "848", "@count": "1", "@label": "Myasthenia gravis"}, {"@id": "407", "@count": "1", "@label": "Muscle wasting disease"}, {"@id": "3354", "@count": "1", "@label": "Wet age related macular degeneration"}, {"@id": "3232", "@count": "1", "@label": "Monkeypox virus infection"}, {"@id": "1676", "@count": "1", "@label": "Wolfram syndrome"}, {"@id": "1823", "@count": "1", "@label": "Methylmalonic acidemia"}, {"@id": "5926", "@count": "1", "@label": "Wolman disease"}, {"@id": "1284", "@count": "1", "@label": "Yellow fever virus infection"}, {"@id": "3239", "@count": "1", "@label": "Portal hypertension"}, {"@id": "3300", "@count": "1", "@label": "Postherpetic neuralgia"}, {"@id": "1259", "@count": "1", "@label": "Pre-eclampsia"}, {"@id": "2887", "@count": "1", "@label": "Polymyalgia rheumatica"}, {"@id": "2970", "@count": "1", "@label": "Phlebovirus infection"}, {"@id": "259", "@count": "1", "@label": "Peripheral neuropathy"}, {"@id": "1113", "@count": "1", "@label": "Pemphigoid"}, {"@id": "1997", "@count": "1", "@label": "Progressive multifocal leukoencephalopathy"}, {"@id": "255", "@count": "1", "@label": "Parkinsons disease"}]}, {"@total": "100", "@label": "Secondary Indications", "@name": "indicationsSecondary", "FilterOption": [{"@id": "1049", "@count": "20", "@label": "Ebola virus infection"}, {"@id": "651", "@count": "14", "@label": "Cancer"}, {"@id": "344", "@count": "11", "@label": "Viral infection"}, {"@id": "725", "@count": "9", "@label": "Solid tumor"}, {"@id": "1048", "@count": "6", "@label": "Marburg virus infection"}, {"@id": "191", "@count": "6", "@label": "Influenza virus infection"}, {"@id": "49", "@count": "5", "@label": "Breast tumor"}, {"@id": "153", "@count": "5", "@label": "Hepatitis C virus infection"}, {"@id": "249", "@count": "4", "@label": "Pancreas tumor"}, {"@id": "158", "@count": "4", "@label": "HIV infection"}, {"@id": "1290", "@count": "3", "@label": "Filovirus infection"}, {"@id": "291", "@count": "3", "@label": "Rheumatoid arthritis"}, {"@id": "152", "@count": "3", "@label": "Hepatitis B virus infection"}, {"@id": "205", "@count": "3", "@label": "Melanoma"}, {"@id": "767", "@count": "3", "@label": "Colon tumor"}, {"@id": "319", "@count": "2", "@label": "Non-Hodgkin lymphoma"}, {"@id": "1262", "@count": "2", "@label": "Non-small-cell lung cancer"}, {"@id": "84", "@count": "2", "@label": "Crohns disease"}, {"@id": "1766", "@count": "2", "@label": "Renal cell carcinoma"}, {"@id": "276", "@count": "2", "@label": "Prostate tumor"}, {"@id": "3246", "@count": "2", "@label": "Hormone refractory prostate cancer"}, {"@id": "159", "@count": "2", "@label": "HIV-1 infection"}, {"@id": "155", "@count": "2", "@label": "Hepatitis virus infection"}, {"@id": "157", "@count": "2", "@label": "Herpes simplex virus infection"}, {"@id": "989", "@count": "2", "@label": "Colorectal tumor"}, {"@id": "1281", "@count": "2", "@label": "West Nile virus infection"}, {"@id": "1828", "@count": "2", "@label": "Multiple myeloma"}, {"@id": "114", "@count": "2", "@label": "Sepsis"}, {"@id": "1143", "@count": "2", "@label": "Amyloidosis"}, {"@id": "31", "@count": "2", "@label": "Asthma"}, {"@id": "755", "@count": "2", "@label": "Lung tumor"}, {"@id": "36", "@count": "2", "@label": "Autoimmune disease"}, {"@id": "39", "@count": "2", "@label": "Bacillus anthracis infection"}, {"@id": "3462", "@count": "1", "@label": "Metastatic liver cancer"}, {"@id": "1114", "@count": "1", "@label": "Pemphigus"}, {"@id": "213", "@count": "1", "@label": "Multiple sclerosis"}, {"@id": "223", "@count": "1", "@label": "Myeloid leukemia"}, {"@id": "251", "@count": "1", "@label": "Papovavirus infection"}, {"@id": "224", "@count": "1", "@label": "Myocardial infarction"}, {"@id": "230", "@count": "1", "@label": "Neoplasm"}, {"@id": "231", "@count": "1", "@label": "Nephritis"}, {"@id": "3288", "@count": "1", "@label": "Non alcoholic fatty liver disease"}, {"@id": "1397", "@count": "1", "@label": "Yersinia pestis infection"}, {"@id": "3503", "@count": "1", "@label": "Viral hemorrhagic fever"}, {"@id": "1812", "@count": "1", "@label": "Viral encephalitis"}, {"@id": "384", "@count": "1", "@label": "Vaccination"}, {"@id": "427", "@count": "1", "@label": "Uterine cervix tumor"}, {"@id": "1076", "@count": "1", "@label": "Thrombosis"}, {"@id": "318", "@count": "1", "@label": "Systemic lupus erythematosus"}, {"@id": "52", "@count": "1", "@label": "Skin burns"}, {"@id": "1783", "@count": "1", "@label": "SARS coronavirus infection"}, {"@id": "3210", "@count": "1", "@label": "Sarcopenia"}, {"@id": "194", "@count": "1", "@label": "Sarcoma"}, {"@id": "330", "@count": "1", "@label": "Restenosis"}, {"@id": "287", "@count": "1", "@label": "Respiratory syncytial virus infection"}, {"@id": "999", "@count": "1", "@label": "Renal tumor"}, {"@id": "286", "@count": "1", "@label": "Renal disease"}, {"@id": "281", "@count": "1", "@label": "Psoriasis"}, {"@id": "1997", "@count": "1", "@label": "Progressive multifocal leukoencephalopathy"}, {"@id": "1060", "@count": "1", "@label": "Precancer"}, {"@id": "274", "@count": "1", "@label": "Pox virus infection"}, {"@id": "268", "@count": "1", "@label": "Plasmodium infection"}, {"@id": "574", "@count": "1", "@label": "Deep vein thrombosis"}, {"@id": "89", "@count": "1", "@label": "Cytomegalovirus infection"}, {"@id": "88", "@count": "1", "@label": "Cystic fibrosis"}, {"@id": "1754", "@count": "1", "@label": "Cutaneous T-cell lymphoma"}, {"@id": "1185", "@count": "1", "@label": "Chronic obstructive pulmonary disease"}, {"@id": "1735", "@count": "1", "@label": "Chronic myelocytic leukemia"}, {"@id": "1734", "@count": "1", "@label": "Chronic lymphocytic leukemia"}, {"@id": "57", "@count": "1", "@label": "Cardiovascular disease"}, {"@id": "3211", "@count": "1", "@label": "Cancer pain"}, {"@id": "791", "@count": "1", "@label": "Burkitts lymphoma"}, {"@id": "760", "@count": "1", "@label": "Brain tumor"}, {"@id": "42", "@count": "1", "@label": "Bladder tumor"}, {"@id": "2369", "@count": "1", "@label": "Beta thalassemia"}, {"@id": "1764", "@count": "1", "@label": "Basal cell carcinoma"}, {"@id": "1030", "@count": "1", "@label": "Arenavirus infection"}, {"@id": "14", "@count": "1", "@label": "Alzheimers disease"}, {"@id": "1285", "@count": "1", "@label": "Alphavirus infection"}, {"@id": "12", "@count": "1", "@label": "Allergy"}, {"@id": "1107", "@count": "1", "@label": "Allergic rhinitis"}, {"@id": "1226", "@count": "1", "@label": "Age related macular degeneration"}, {"@id": "1069", "@count": "1", "@label": "Metastasis"}, {"@id": "1746", "@count": "1", "@label": "Marginal zone B-cell lymphoma"}, {"@id": "203", "@count": "1", "@label": "Lymphoma"}, {"@id": "199", "@count": "1", "@label": "Leukemia"}, {"@id": "2446", "@count": "1", "@label": "Leiomyosarcoma"}, {"@id": "1140", "@count": "1", "@label": "Jaundice"}, {"@id": "752", "@count": "1", "@label": "Intoxication"}, {"@id": "188", "@count": "1", "@label": "Inflammatory disease"}, {"@id": "189", "@count": "1", "@label": "Inflammatory bowel disease"}, {"@id": "746", "@count": "1", "@label": "Infectious disease"}, {"@id": "504", "@count": "1", "@label": "Immune deficiency"}, {"@id": "174", "@count": "1", "@label": "Hypercholesterolemia"}, {"@id": "1124", "@count": "1", "@label": "Herpesvirus infection"}, {"@id": "623", "@count": "1", "@label": "Head and neck tumor"}, {"@id": "616", "@count": "1", "@label": "Graft versus host disease"}, {"@id": "1745", "@count": "1", "@label": "Follicle center lymphoma"}, {"@id": "2020", "@count": "1", "@label": "Duchenne dystrophy"}, {"@id": "2475", "@count": "1", "@label": "Dermatomyositis"}]}, {"@total": "83", "@label": "Secondary Actions", "@name": "actionsSecondary", "FilterOption": [{"@id": "991", "@count": "104", "@label": "Antiviral"}, {"@id": "59620", "@count": "42", "@label": "Unspecified drug target"}, {"@id": "12378", "@count": "39", "@label": "Prophylactic vaccine"}, {"@id": "1545", "@count": "35", "@label": "Anticancer"}, {"@id": "767", "@count": "30", "@label": "Cell cycle inhibitor"}, {"@id": "2575", "@count": "29", "@label": "Microtubule inhibitor"}, {"@id": "12370", "@count": "27", "@label": "Recombinant viral vector vaccine"}, {"@id": "2953", "@count": "21", "@label": "Anti-inflammatory"}, {"@id": "12379", "@count": "20", "@label": "Therapeutic vaccine"}, {"@id": "1879", "@count": "17", "@label": "DNA vaccine"}, {"@id": "12372", "@count": "11", "@label": "Protein subunit vaccine"}, {"@id": "7294", "@count": "11", "@label": "Antisense oligonucleotide inhibitor"}, {"@id": "26035", "@count": "11", "@label": "siRNA agent"}, {"@id": "393", "@count": "8", "@label": "Immunostimulant"}, {"@id": "721", "@count": "7", "@label": "TNF binding agent"}, {"@id": "1532", "@count": "7", "@label": "Viral replication inhibitor"}, {"@id": "55685", "@count": "6", "@label": "Anticancer monoclonal antibody"}, {"@id": "1596", "@count": "6", "@label": "Immunomodulator"}, {"@id": "140", "@count": "6", "@label": "DNA synthesis inhibitor"}, {"@id": "12380", "@count": "5", "@label": "Unspecified vaccine"}, {"@id": "1832", "@count": "5", "@label": "Nucleoside reverse transcriptase inhibitor"}, {"@id": "1569", "@count": "4", "@label": "Anticancer antimetabolite"}, {"@id": "1594", "@count": "4", "@label": "Antibacterial"}, {"@id": "399", "@count": "4", "@label": "Hypoglycemic agent"}, {"@id": "747", "@count": "4", "@label": "HIV replication inhibitor"}, {"@id": "15184", "@count": "4", "@label": "Systemic antipsoriatic product"}, {"@id": "12371", "@count": "3", "@label": "Subunit vaccine"}, {"@id": "2576", "@count": "3", "@label": "Microtubule stabilizer"}, {"@id": "1615", "@count": "3", "@label": "Neuroprotectant"}, {"@id": "15128", "@count": "3", "@label": "Ophthalmological agent"}, {"@id": "2946", "@count": "3", "@label": "Analgesic"}, {"@id": "71", "@count": "3", "@label": "Antihypercholesterolemic agent"}, {"@id": "4780", "@count": "3", "@label": "Adenovirus based gene therapy"}, {"@id": "524", "@count": "3", "@label": "Adjuvant"}, {"@id": "50", "@count": "2", "@label": "Anticancer alkylating agent"}, {"@id": "12364", "@count": "2", "@label": "Live attenuated viral vaccine"}, {"@id": "439", "@count": "2", "@label": "RNA synthesis inhibitor"}, {"@id": "12367", "@count": "2", "@label": "Inactivated viral vaccine"}, {"@id": "2657", "@count": "2", "@label": "Antihypertensive"}, {"@id": "621", "@count": "2", "@label": "Amyloid protein deposition inhibitor"}, {"@id": "1589", "@count": "2", "@label": "Apoptosis stimulator"}, {"@id": "863", "@count": "2", "@label": "Bile acid modulator"}, {"@id": "2659", "@count": "2", "@label": "Cardioprotectant"}, {"@id": "1720", "@count": "2", "@label": "Virus uptake inhibitor"}, {"@id": "463", "@count": "1", "@label": "Ribosome binding agent"}, {"@id": "15132", "@count": "1", "@label": "Ophthalmological antiviral"}, {"@id": "26034", "@count": "1", "@label": "RNA interference agent"}, {"@id": "7292", "@count": "1", "@label": "Vulnerary agent"}, {"@id": "2660", "@count": "1", "@label": "Vasoprotectant"}, {"@id": "12377", "@count": "1", "@label": "RNA vaccine"}, {"@id": "2969", "@count": "1", "@label": "Vascular damaging agent"}, {"@id": "386", "@count": "1", "@label": "Vaccine"}, {"@id": "7293", "@count": "1", "@label": "Synergist"}, {"@id": "3510", "@count": "1", "@label": "TNF release modulator"}, {"@id": "7761", "@count": "1", "@label": "T-lymphocyte stimulator"}, {"@id": "15190", "@count": "1", "@label": "Systemic dermatological antiviral product"}, {"@id": "5692", "@count": "1", "@label": "T-lymphocyte modulator"}, {"@id": "3", "@count": "1", "@label": "5-HT uptake inhibitor"}, {"@id": "633", "@count": "1", "@label": "Acetylcholine release stimulator"}, {"@id": "2667", "@count": "1", "@label": "Antiarteriosclerotic"}, {"@id": "2941", "@count": "1", "@label": "Antidepressant"}, {"@id": "4007", "@count": "1", "@label": "Antidiarrhoeal"}, {"@id": "1593", "@count": "1", "@label": "Antimicrobial"}, {"@id": "74", "@count": "1", "@label": "Antioxidant agent"}, {"@id": "2947", "@count": "1", "@label": "Antiparkinsonian"}, {"@id": "1590", "@count": "1", "@label": "Apoptosis inhibitor"}, {"@id": "1546", "@count": "1", "@label": "Blood system agent"}, {"@id": "965", "@count": "1", "@label": "Cardiovascular agent"}, {"@id": "2939", "@count": "1", "@label": "CNS modulator"}, {"@id": "659", "@count": "1", "@label": "Coagulation inhibitor"}, {"@id": "3189", "@count": "1", "@label": "Corticosteroid agonist"}, {"@id": "166", "@count": "1", "@label": "Fibrinolysis stimulator"}, {"@id": "4994", "@count": "1", "@label": "IL release stimulator"}, {"@id": "396", "@count": "1", "@label": "Immunosuppressant"}, {"@id": "32415", "@count": "1", "@label": "Influenza A virus replication inhibitor"}, {"@id": "1919", "@count": "1", "@label": "Insulin sensitizer"}, {"@id": "1389", "@count": "1", "@label": "Lipid metabolism modulator"}, {"@id": "1408", "@count": "1", "@label": "Muscle system agent"}, {"@id": "7757", "@count": "1", "@label": "Natural killer cell stimulator"}, {"@id": "450", "@count": "1", "@label": "Neuromuscular blocking agent"}, {"@id": "284", "@count": "1", "@label": "Nootropic agent"}, {"@id": "285", "@count": "1", "@label": "Norepinephrine uptake inhibitor"}, {"@id": "12376", "@count": "1", "@label": "Nucleic acid vaccine"}]}, {"@total": "100", "@label": "Secondary Companies", "@name": "companiesSecondary", "FilterOption": [{"@id": "14240", "@count": "8", "@label": "Sarepta Therapeutics Inc"}, {"@id": "17254", "@count": "6", "@label": "Crucell NV"}, {"@id": "29562", "@count": "6", "@label": "GenPhar Inc"}, {"@id": "30578", "@count": "5", "@label": "VGX Pharmaceuticals LLC"}, {"@id": "14199", "@count": "4", "@label": "Wyeth Pharmaceuticals"}, {"@id": "29653", "@count": "4", "@label": "Functional Genetics Inc"}, {"@id": "14184", "@count": "4", "@label": "US Army Medical Research Institute of Infectious Diseases"}, {"@id": "20524", "@count": "3", "@label": "University of Alabama at Birmingham"}, {"@id": "16450", "@count": "3", "@label": "Gilead Sciences Inc"}, {"@id": "16173", "@count": "3", "@label": "Inex Pharmaceuticals Corp"}, {"@id": "28467", "@count": "3", "@label": "Protiva Biotherapeutics Inc"}, {"@id": "23137", "@count": "3", "@label": "Novartis AG"}, {"@id": "29927", "@count": "3", "@label": "Alnylam Pharmaceuticals Inc"}, {"@id": "18077", "@count": "3", "@label": "Merck & Co Inc"}, {"@id": "20518", "@count": "3", "@label": "National Institutes of Health"}, {"@id": "24727", "@count": "2", "@label": "Rega Institute for Medical Research"}, {"@id": "22127", "@count": "2", "@label": "Sanofi Pasteur"}, {"@id": "28355", "@count": "2", "@label": "GlaxoSmithKline plc"}, {"@id": "23940", "@count": "2", "@label": "NeoPharm Inc"}, {"@id": "28907", "@count": "2", "@label": "Microbiotix Inc"}, {"@id": "18630", "@count": "2", "@label": "State Research Center of Virology and Biotechnology VECTOR"}, {"@id": "15873", "@count": "2", "@label": "Elan Corp plc"}, {"@id": "1010798", "@count": "2", "@label": "Talon Therapeutics Inc"}, {"@id": "27711", "@count": "2", "@label": "CytoGenix Inc"}, {"@id": "14695", "@count": "2", "@label": "BioCryst Pharmaceuticals Inc"}, {"@id": "14188", "@count": "2", "@label": "Biomolecular Research Institute Ltd"}, {"@id": "19046", "@count": "2", "@label": "ViroPharma Inc"}, {"@id": "14129", "@count": "2", "@label": "Cangene Corp"}, {"@id": "24236", "@count": "2", "@label": "Cambridge Antibody Technology Group plc"}, {"@id": "20658", "@count": "1", "@label": "University of Pennsylvania"}, {"@id": "21864", "@count": "1", "@label": "University of Texas System"}, {"@id": "20690", "@count": "1", "@label": "University of Utah"}, {"@id": "17592", "@count": "1", "@label": "RW Johnson Pharmaceutical Research Institute"}, {"@id": "19298", "@count": "1", "@label": "Rhone-Poulenc Rorer Ltd"}, {"@id": "19365", "@count": "1", "@label": "Rhone-Poulenc Rorer Inc"}, {"@id": "25813", "@count": "1", "@label": "Vaxin Inc"}, {"@id": "20743", "@count": "1", "@label": "Vical Inc"}, {"@id": "1016204", "@count": "1", "@label": "ProQinase GmbH"}, {"@id": "15956", "@count": "1", "@label": "Principia Pharmaceutical Corp"}, {"@id": "24380", "@count": "1", "@label": "PNO Resources Ltd"}, {"@id": "21254", "@count": "1", "@label": "Paracelsian Inc"}, {"@id": "29975", "@count": "1", "@label": "Omniviral Therapeutics LLC"}, {"@id": "24803", "@count": "1", "@label": "Viragen Inc"}, {"@id": "19447", "@count": "1", "@label": "Nippon Roche KK"}, {"@id": "15906", "@count": "1", "@label": "NeXstar Pharmaceuticals Inc"}, {"@id": "1008260", "@count": "1", "@label": "NexBio Inc"}, {"@id": "1042873", "@count": "1", "@label": "neuMirRx Corp"}, {"@id": "14112", "@count": "1", "@label": "Wyeth"}, {"@id": "22124", "@count": "1", "@label": "XTL Biopharmaceuticals Ltd"}, {"@id": "17221", "@count": "1", "@label": "Nektar Therapeutics"}, {"@id": "20978", "@count": "1", "@label": "Yissum Research Development Co"}, {"@id": "1023145", "@count": "1", "@label": "Trius Therapeutics Inc"}, {"@id": "22659", "@count": "1", "@label": "Triangle Pharmaceuticals Inc"}, {"@id": "20371", "@count": "1", "@label": "Therion Biologics Corp"}, {"@id": "21241", "@count": "1", "@label": "The University of Aston In Birmingham"}, {"@id": "21105", "@count": "1", "@label": "Texas Biomedical Research Institute"}, {"@id": "1032153", "@count": "1", "@label": "Tekmira Pharmaceuticals Corp"}, {"@id": "20315", "@count": "1", "@label": "Tanabe Seiyaku Co Ltd"}, {"@id": "27164", "@count": "1", "@label": "Tumor Biology Center, Freiburg"}, {"@id": "20289", "@count": "1", "@label": "Taisho Pharmaceutical Co Ltd"}, {"@id": "14911", "@count": "1", "@label": "Sumitomo Pharmaceuticals Co Ltd"}, {"@id": "24119", "@count": "1", "@label": "Universita di Perugia"}, {"@id": "26880", "@count": "1", "@label": "State University of New York"}, {"@id": "1006257", "@count": "1", "@label": "University of Alabama"}, {"@id": "26483", "@count": "1", "@label": "Starpharma Holdings Ltd"}, {"@id": "24155", "@count": "1", "@label": "SmithKline Beecham Corp"}, {"@id": "25692", "@count": "1", "@label": "SMI Genzyme Ltd"}, {"@id": "24652", "@count": "1", "@label": "Shire plc"}, {"@id": "14691", "@count": "1", "@label": "Shire BioChem Inc"}, {"@id": "1014697", "@count": "1", "@label": "SD Pharmaceuticals Inc"}, {"@id": "21102", "@count": "1", "@label": "Scripps Research Institute"}, {"@id": "1010952", "@count": "1", "@label": "SCOLR Pharma Inc"}, {"@id": "20532", "@count": "1", "@label": "University of British Columbia"}, {"@id": "19829", "@count": "1", "@label": "SciClone Pharmaceuticals Inc"}, {"@id": "20623", "@count": "1", "@label": "University of Michigan"}, {"@id": "23738", "@count": "1", "@label": "Schwarz Pharma Inc"}, {"@id": "26414", "@count": "1", "@label": "Elan Pharmaceuticals Inc"}, {"@id": "15546", "@count": "1", "@label": "Dendreon San Diego LLC"}, {"@id": "23109", "@count": "1", "@label": "Dalhousie University"}, {"@id": "15587", "@count": "1", "@label": "Daewoong Pharmaceutical Co Ltd"}, {"@id": "1006511", "@count": "1", "@label": "Cornerstone Pharmaceuticals Inc"}, {"@id": "DOL1000826", "@count": "1", "@label": "Cook Group Inc"}, {"@id": "1018927", "@count": "1", "@label": "Contraceptive Research and Development Organization"}, {"@id": "27288", "@count": "1", "@label": "Coley Pharmaceutical Group Inc"}, {"@id": "15414", "@count": "1", "@label": "Chugai Pharmaceutical Co Ltd"}, {"@id": "1060168", "@count": "1", "@label": "Centre for Drug Research and Development"}, {"@id": "15331", "@count": "1", "@label": "Celgene Corp"}, {"@id": "24077", "@count": "1", "@label": "Cancer Research Campaign Technology Ltd"}, {"@id": "26864", "@count": "1", "@label": "Bristol-Myers Squibb Pharma Co"}, {"@id": "1025424", "@count": "1", "@label": "Brightgene Bio-Medical Technology Co Ltd"}, {"@id": "14832", "@count": "1", "@label": "Biosyn Inc"}, {"@id": "1005244", "@count": "1", "@label": "Biogen Idec Inc"}, {"@id": "1019862", "@count": "1", "@label": "BioFactura Inc"}, {"@id": "24093", "@count": "1", "@label": "BASF Pharma"}, {"@id": "1007966", "@count": "1", "@label": "Azaya Therapeutics Inc"}, {"@id": "25218", "@count": "1", "@label": "Aventis Pharma AG"}, {"@id": "23063", "@count": "1", "@label": "Aventis Behring LLC"}, {"@id": "26942", "@count": "1", "@label": "ATIII LLC"}, {"@id": "14289", "@count": "1", "@label": "Aradigm Corp"}, {"@id": "1002809", "@count": "1", "@label": "Apath LLC"}]}, {"@total": "88", "@label": "Primary Actions", "@name": "actionsPrimary", "FilterOption": [{"@id": "381", "@count": "7", "@label": "TNF alpha ligand inhibitor"}, {"@id": "447", "@count": "6", "@label": "Exo-alpha sialidase inhibitor"}, {"@id": "138", "@count": "6", "@label": "DNA polymerase inhibitor"}, {"@id": "1016", "@count": "4", "@label": "HIV-1 reverse transcriptase inhibitor"}, {"@id": "35464", "@count": "4", "@label": "Viral envelope glycoprotein inhibitor"}, {"@id": "52120", "@count": "4", "@label": "Hemagglutinin modulator"}, {"@id": "214", "@count": "3", "@label": "Interferon alpha 2 ligand"}, {"@id": "483", "@count": "3", "@label": "Interferon alpha ligand"}, {"@id": "46994", "@count": "2", "@label": "VP35 gene inhibitor"}, {"@id": "22390", "@count": "2", "@label": "TTR gene inhibitor"}, {"@id": "5738", "@count": "2", "@label": "Immunoglobulin G agonist"}, {"@id": "7827", "@count": "2", "@label": "TLR-9 agonist"}, {"@id": "281", "@count": "2", "@label": "NMDA receptor antagonist"}, {"@id": "81927", "@count": "2", "@label": "Complement C5 factor inhibitor"}, {"@id": "12393", "@count": "2", "@label": "HIV GAG protein modulator"}, {"@id": "347", "@count": "2", "@label": "RNA polymerase inhibitor"}, {"@id": "6512", "@count": "2", "@label": "DNA methyltransferase inhibitor"}, {"@id": "62405", "@count": "2", "@label": "VP24 gene inhibitor"}, {"@id": "3033", "@count": "1", "@label": "PPAR alpha agonist"}, {"@id": "16995", "@count": "1", "@label": "VEGF gene inhibitor"}, {"@id": "46203", "@count": "1", "@label": "PLK1 gene modulator"}, {"@id": "15968", "@count": "1", "@label": "PCSK9 gene inhibitor"}, {"@id": "14613", "@count": "1", "@label": "Myc proto-oncogene protein modulator"}, {"@id": "5182", "@count": "1", "@label": "Membrane cofactor protein inhibitor"}, {"@id": "48507", "@count": "1", "@label": "Major envelope protein p37 inhibitor"}, {"@id": "545", "@count": "1", "@label": "Lipase stimulator"}, {"@id": "16274", "@count": "1", "@label": "KIF11 gene inhibitor"}, {"@id": "513", "@count": "1", "@label": "Kallikrein inhibitor"}, {"@id": "917", "@count": "1", "@label": "Interferon alpha ligand modulator"}, {"@id": "30011", "@count": "1", "@label": "Wilms tumor protein inhibitor"}, {"@id": "36783", "@count": "1", "@label": "Tumor susceptibility gene protein 101 inhibitor"}, {"@id": "12767", "@count": "1", "@label": "Tumor necrosis factor ligand inhibitor"}, {"@id": "11256", "@count": "1", "@label": "Transthyretin modulator"}, {"@id": "9320", "@count": "1", "@label": "Topoisomerase IV inhibitor"}, {"@id": "141", "@count": "1", "@label": "Topoisomerase I inhibitor"}, {"@id": "36781", "@count": "1", "@label": "Tumor susceptibility gene protein 101 modulator"}, {"@id": "7809", "@count": "1", "@label": "TLR-3 agonist"}, {"@id": "359", "@count": "1", "@label": "TAT protein inhibitor"}, {"@id": "58024", "@count": "1", "@label": "Slit homolog 2 protein modulator"}, {"@id": "7797", "@count": "1", "@label": "Unspecified gene inhibitor"}, {"@id": "60790", "@count": "1", "@label": "Roundabout homolog 4 stimulator"}, {"@id": "9671", "@count": "1", "@label": "Unspecified protein kinase inhibitor"}, {"@id": "551", "@count": "1", "@label": "RNA DNA polymerase inhibitor"}, {"@id": "346", "@count": "1", "@label": "Ribonucleotide reductase inhibitor"}, {"@id": "52990", "@count": "1", "@label": "Regulator of nonsense transcripts modulator"}, {"@id": "385", "@count": "1", "@label": "Protein tyrosine kinase inhibitor"}, {"@id": "37415", "@count": "1", "@label": "Protein ARMET stimulator"}, {"@id": "3971", "@count": "1", "@label": "PPAR delta agonist"}, {"@id": "9656", "@count": "1", "@label": "Dystrophin stimulator"}, {"@id": "71209", "@count": "1", "@label": "DNA gyrase B inhibitor"}, {"@id": "5482", "@count": "1", "@label": "Cytotoxic T-lymphocyte protein-4 inhibitor"}, {"@id": "15172", "@count": "1", "@label": "Complement C1s subcomponent inhibitor"}, {"@id": "52420", "@count": "1", "@label": "CMV 65kDa lower matrix phosphoprotein modulator"}, {"@id": "776", "@count": "1", "@label": "Chloride channel stimulator"}, {"@id": "5123", "@count": "1", "@label": "CD34 agonist"}, {"@id": "3101", "@count": "1", "@label": "CCR3 chemokine antagonist"}, {"@id": "1911", "@count": "1", "@label": "Cathepsin L modulator"}, {"@id": "1269", "@count": "1", "@label": "Cathepsin B modulator"}, {"@id": "7298", "@count": "1", "@label": "Caspase-2 modulator"}, {"@id": "26266", "@count": "1", "@label": "APOB gene inhibitor"}, {"@id": "75", "@count": "1", "@label": "Antithrombin III"}, {"@id": "8805", "@count": "1", "@label": "AMP activated protein kinase stimulator"}, {"@id": "27904", "@count": "1", "@label": "Aldehyde dehydrogenase 2 inhibitor"}, {"@id": "815", "@count": "1", "@label": "Albumin modulator"}, {"@id": "23", "@count": "1", "@label": "Adenosine receptor antagonist"}, {"@id": "4574", "@count": "1", "@label": "Activin type-IIB receptor antagonist"}, {"@id": "6284", "@count": "1", "@label": "Actin antagonist"}, {"@id": "162", "@count": "1", "@label": "Acetylcholine receptor antagonist"}, {"@id": "212", "@count": "1", "@label": "Interferon agonist"}, {"@id": "33681", "@count": "1", "@label": "Influenza matrix protein modulator"}, {"@id": "33689", "@count": "1", "@label": "Influenza matrix protein 2 inhibitor"}, {"@id": "5731", "@count": "1", "@label": "Immunoglobulin agonist"}, {"@id": "9748", "@count": "1", "@label": "IL-23 antagonist"}, {"@id": "1584", "@count": "1", "@label": "IL-12 antagonist"}, {"@id": "430", "@count": "1", "@label": "Hydrolase inhibitor"}, {"@id": "8012", "@count": "1", "@label": "Hsp 90 inhibitor"}, {"@id": "11208", "@count": "1", "@label": "HIV gp160 protein modulator"}, {"@id": "71849", "@count": "1", "@label": "HIV GAG POL polyprotein modulator"}, {"@id": "35453", "@count": "1", "@label": "HIV env gene modulator"}, {"@id": "12347", "@count": "1", "@label": "Hepatitis C virus NS3 protease modulator"}, {"@id": "52122", "@count": "1", "@label": "Hemagglutinin inhibitor"}, {"@id": "7928", "@count": "1", "@label": "GDF-8 antagonist"}, {"@id": "9979", "@count": "1", "@label": "Galectin-3 inhibitor"}, {"@id": "62226", "@count": "1", "@label": "GAG gene modulator"}, {"@id": "4039", "@count": "1", "@label": "Farnesoid X receptor agonist"}, {"@id": "114", "@count": "1", "@label": "Factor VII antagonist"}, {"@id": "1483", "@count": "1", "@label": "Exo-alpha sialidase modulator"}, {"@id": "17389", "@count": "1", "@label": "Eotaxin ligand inhibitor"}]}, {"@total": "100", "@label": "Primary Companies", "@name": "companiesPrimary", "FilterOption": [{"@id": "22403", "@count": "9", "@label": "Inovio Pharmaceuticals Inc"}, {"@id": "1014809", "@count": "7", "@label": "NanoViricides Inc"}, {"@id": "1021184", "@count": "7", "@label": "Profectus BioSciences Inc"}, {"@id": "1032153", "@count": "5", "@label": "Tekmira Pharmaceuticals Corp"}, {"@id": "1045710", "@count": "5", "@label": "Defyrus Inc"}, {"@id": "20518", "@count": "5", "@label": "National Institutes of Health"}, {"@id": "1043985", "@count": "4", "@label": "VGX International"}, {"@id": "29927", "@count": "4", "@label": "Alnylam Pharmaceuticals Inc"}, {"@id": "28355", "@count": "4", "@label": "GlaxoSmithKline plc"}, {"@id": "14184", "@count": "4", "@label": "US Army Medical Research Institute of Infectious Diseases"}, {"@id": "14695", "@count": "4", "@label": "BioCryst Pharmaceuticals Inc"}, {"@id": "1043354", "@count": "3", "@label": "Mapp Biopharmaceutical Inc"}, {"@id": "18767", "@count": "3", "@label": "Pfizer Inc"}, {"@id": "18077", "@count": "3", "@label": "Merck & Co Inc"}, {"@id": "1008830", "@count": "3", "@label": "Prosetta Antiviral Inc"}, {"@id": "14240", "@count": "3", "@label": "Sarepta Therapeutics Inc"}, {"@id": "19711", "@count": "3", "@label": "Schering-Plough Corp"}, {"@id": "24949", "@count": "3", "@label": "SIGA Technologies Inc"}, {"@id": "24232", "@count": "3", "@label": "Spectrum Pharmaceuticals Inc"}, {"@id": "17254", "@count": "3", "@label": "Crucell NV"}, {"@id": "20520", "@count": "3", "@label": "National Institute of Allergy and Infectious Diseases"}, {"@id": "15065", "@count": "3", "@label": "Bristol-Myers Squibb Co"}, {"@id": "1053945", "@count": "2", "@label": "Immune Pharmaceuticals Inc"}, {"@id": "19446", "@count": "2", "@label": "Roche Holding AG"}, {"@id": "23369", "@count": "2", "@label": "Samyang Corp"}, {"@id": "1020743", "@count": "2", "@label": "GP Pharm SA"}, {"@id": "18436", "@count": "2", "@label": "Philip Morris Products Inc"}, {"@id": "16450", "@count": "2", "@label": "Gilead Sciences Inc"}, {"@id": "25623", "@count": "2", "@label": "University of California Los Angeles"}, {"@id": "19896", "@count": "2", "@label": "Shin Poong Pharmaceutical Co Ltd"}, {"@id": "24244", "@count": "2", "@label": "Bavarian Nordic A/S"}, {"@id": "29954", "@count": "2", "@label": "TTY Biopharm Co Ltd"}, {"@id": "15742", "@count": "2", "@label": "Dong-A ST Co Ltd"}, {"@id": "23137", "@count": "2", "@label": "Novartis AG"}, {"@id": "1049926", "@count": "2", "@label": "Navigen Inc"}, {"@id": "1035060", "@count": "2", "@label": "Mitsubishi Tanabe Pharma Corp"}, {"@id": "26417", "@count": "2", "@label": "AlphaVax Inc"}, {"@id": "20519", "@count": "2", "@label": "National Cancer Institute"}, {"@id": "1014618", "@count": "2", "@label": "Medicago Inc"}, {"@id": "1043995", "@count": "1", "@label": "Providence Cancer Center, Earle A. Chiles Research Institute"}, {"@id": "1040227", "@count": "1", "@label": "US WorldMeds LLC"}, {"@id": "1022888", "@count": "1", "@label": "Vaxart Inc"}, {"@id": "17608", "@count": "1", "@label": "Xian-Janssen Pharmaceutical Ltd"}, {"@id": "1063023", "@count": "1", "@label": "ProPreven"}, {"@id": "28066", "@count": "1", "@label": "PTC Therapeutics Inc"}, {"@id": "1050515", "@count": "1", "@label": "ViiV Healthcare"}, {"@id": "26334", "@count": "1", "@label": "National Institute of Diabetes, Digestive and Kidney Diseases"}, {"@id": "1033989", "@count": "1", "@label": "PPD Inc"}, {"@id": "1021080", "@count": "1", "@label": "Viropro Inc"}, {"@id": "14775", "@count": "1", "@label": "ViraNative AB"}, {"@id": "20984", "@count": "1", "@label": "Yuhan Corp"}, {"@id": "20325", "@count": "1", "@label": "Peregrine Pharmaceuticals Inc"}, {"@id": "23407", "@count": "1", "@label": "Pasteur Merieux"}, {"@id": "1041297", "@count": "1", "@label": "PanThera Biopharma LLC"}, {"@id": "1075056", "@count": "1", "@label": "Orygen Biotecnologia Ltda"}, {"@id": "1010647", "@count": "1", "@label": "NeoStem Inc"}, {"@id": "1042038", "@count": "1", "@label": "Ontario Institute for Cancer Research"}, {"@id": "1006413", "@count": "1", "@label": "Oncovir Inc"}, {"@id": "1035490", "@count": "1", "@label": "Okairos"}, {"@id": "30579", "@count": "1", "@label": "Nuvelo Inc"}, {"@id": "1020606", "@count": "1", "@label": "Novartis Vaccines & Diagnostics"}, {"@id": "19046", "@count": "1", "@label": "ViroPharma Inc"}, {"@id": "25599", "@count": "1", "@label": "Novartis Pharma AG"}, {"@id": "18535", "@count": "1", "@label": "Nippon Kayaku Co Ltd"}, {"@id": "19447", "@count": "1", "@label": "Nippon Roche KK"}, {"@id": "1076856", "@count": "1", "@label": "SKAU Vaccines ApS"}, {"@id": "19962", "@count": "1", "@label": "SmithKline Beecham plc"}, {"@id": "1024119", "@count": "1", "@label": "Solstice Neurosciences Inc"}, {"@id": "20678", "@count": "1", "@label": "Southampton University"}, {"@id": "20424", "@count": "1", "@label": "Toyama Chemical Co Ltd"}, {"@id": "26483", "@count": "1", "@label": "Starpharma Holdings Ltd"}, {"@id": "1035705", "@count": "1", "@label": "Sun Pharmaceutical Advanced Research Co Ltd"}, {"@id": "23509", "@count": "1", "@label": "Supratek Pharma Inc"}, {"@id": "20277", "@count": "1", "@label": "Swedish Orphan AB"}, {"@id": "31234", "@count": "1", "@label": "Synageva BioPharma Corp"}, {"@id": "30180", "@count": "1", "@label": "Synta Pharmaceuticals Corp"}, {"@id": "1010798", "@count": "1", "@label": "Talon Therapeutics Inc"}, {"@id": "1063582", "@count": "1", "@label": "TherDose Pharma Pvt Ltd"}, {"@id": "20348", "@count": "1", "@label": "Teva Pharmaceutical Industries Ltd"}, {"@id": "24653", "@count": "1", "@label": "The Medicines Company"}, {"@id": "1062927", "@count": "1", "@label": "The Technology Innovation Agency"}, {"@id": "1075267", "@count": "1", "@label": "Thelial Technologies SA"}, {"@id": "21266", "@count": "1", "@label": "Ranbaxy Laboratories Ltd"}, {"@id": "29809", "@count": "1", "@label": "REPLICor Inc"}, {"@id": "25900", "@count": "1", "@label": "rEVO Biologics Inc"}, {"@id": "19365", "@count": "1", "@label": "Rhone-Poulenc Rorer Inc"}, {"@id": "25471", "@count": "1", "@label": "Rigel Pharmaceuticals Inc"}, {"@id": "1071703", "@count": "1", "@label": "Samsung Bioepis Co Ltd"}, {"@id": "1009547", "@count": "1", "@label": "Sanofi"}, {"@id": "26495", "@count": "1", "@label": "Sanofi (pre-1999)"}, {"@id": "1069084", "@count": "1", "@label": "US Army Medical Research and Materiel Command"}, {"@id": "27531", "@count": "1", "@label": "Sanquin Blood Supply Foundation"}, {"@id": "20594", "@count": "1", "@label": "University of Iowa"}, {"@id": "1032695", "@count": "1", "@label": "SciDose LLC"}, {"@id": "21102", "@count": "1", "@label": "Scripps Research Institute"}, {"@id": "1012768", "@count": "1", "@label": "Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd"}, {"@id": "1060612", "@count": "1", "@label": "Shanghai Pharmaceuticals Holding Co Ltd"}, {"@id": "19898", "@count": "1", "@label": "Shionogi & Co Ltd"}, {"@id": "1090666", "@count": "1", "@label": "Sitka Biopharma Inc"}, {"@id": "26914", "@count": "1", "@label": "SK Chemicals Co Ltd"}]}, {"@total": "14", "@label": "Drug Deal Types", "@name": "drugDealTypes", "FilterOption": [{"@id": "13", "@count": "74", "@label": "Drug - Funding"}, {"@id": "4", "@count": "69", "@label": "Drug - Development/Commercialization License"}, {"@id": "3", "@count": "30", "@label": "Drug - Early Research/Development"}, {"@id": "5", "@count": "26", "@label": "Drug - Commercialization License"}, {"@id": "7", "@count": "25", "@label": "Drug - Development Services"}, {"@id": "6", "@count": "23", "@label": "Drug - Manufacturing/Supply"}, {"@id": "15", "@count": "20", "@label": "Drug - CRADA"}, {"@id": "10", "@count": "19", "@label": "Technology - Other Proprietary"}, {"@id": "11", "@count": "18", "@label": "Patent - Exclusive Rights"}, {"@id": "8", "@count": "14", "@label": "Technology - Delivery/Formulation"}, {"@id": "2", "@count": "10", "@label": "Drug - Screening/Evaluation"}, {"@id": "14", "@count": "5", "@label": "Drug - Asset Divestment"}, {"@id": "12", "@count": "3", "@label": "Patent - Non-Exclusive Rights"}, {"@id": "1", "@count": "1", "@label": "Drug - Discovery/Design"}]}, {"@total": "100", "@label": "Drug Added by Day", "@name": "drugAddedDateByDay", "FilterOption": [{"@count": "15", "@label": "1996-02-16"}, {"@count": "4", "@label": "2002-04-02"}, {"@count": "3", "@label": "2008-10-10"}, {"@count": "2", "@label": "2001-03-13"}, {"@count": "2", "@label": "2002-11-13"}, {"@count": "2", "@label": "2005-01-06"}, {"@count": "2", "@label": "2005-10-17"}, {"@count": "2", "@label": "2007-05-24"}, {"@count": "2", "@label": "2007-06-01"}, {"@count": "2", "@label": "2008-05-13"}, {"@count": "2", "@label": "2010-07-16"}, {"@count": "2", "@label": "2010-07-19"}, {"@count": "2", "@label": "2011-07-14"}, {"@count": "2", "@label": "2012-05-24"}, {"@count": "2", "@label": "2012-07-06"}, {"@count": "2", "@label": "2012-08-01"}, {"@count": "2", "@label": "2013-01-03"}, {"@count": "2", "@label": "2013-05-15"}, {"@count": "2", "@label": "2013-08-14"}, {"@count": "2", "@label": "2013-09-18"}, {"@count": "2", "@label": "1996-07-02"}, {"@count": "1", "@label": "2010-06-22"}, {"@count": "1", "@label": "2010-06-24"}, {"@count": "1", "@label": "1997-02-07"}, {"@count": "1", "@label": "1996-11-01"}, {"@count": "1", "@label": "2010-07-20"}, {"@count": "1", "@label": "2010-08-04"}, {"@count": "1", "@label": "2010-08-12"}, {"@count": "1", "@label": "2010-08-13"}, {"@count": "1", "@label": "2010-09-27"}, {"@count": "1", "@label": "2010-10-14"}, {"@count": "1", "@label": "2010-10-22"}, {"@count": "1", "@label": "2010-10-29"}, {"@count": "1", "@label": "2010-12-10"}, {"@count": "1", "@label": "2011-01-24"}, {"@count": "1", "@label": "2011-02-01"}, {"@count": "1", "@label": "2011-02-25"}, {"@count": "1", "@label": "2011-03-02"}, {"@count": "1", "@label": "2011-03-21"}, {"@count": "1", "@label": "2011-04-13"}, {"@count": "1", "@label": "2011-04-20"}, {"@count": "1", "@label": "2011-05-25"}, {"@count": "1", "@label": "2011-06-27"}, {"@count": "1", "@label": "2008-11-06"}, {"@count": "1", "@label": "2008-12-09"}, {"@count": "1", "@label": "2008-12-19"}, {"@count": "1", "@label": "2009-03-04"}, {"@count": "1", "@label": "2009-05-06"}, {"@count": "1", "@label": "2009-05-12"}, {"@count": "1", "@label": "2009-05-26"}, {"@count": "1", "@label": "2009-06-03"}, {"@count": "1", "@label": "2009-06-30"}, {"@count": "1", "@label": "2009-07-01"}, {"@count": "1", "@label": "2009-07-22"}, {"@count": "1", "@label": "2009-08-05"}, {"@count": "1", "@label": "2009-08-11"}, {"@count": "1", "@label": "2009-08-27"}, {"@count": "1", "@label": "2009-09-23"}, {"@count": "1", "@label": "2009-10-27"}, {"@count": "1", "@label": "2010-01-04"}, {"@count": "1", "@label": "2010-01-11"}, {"@count": "1", "@label": "2010-04-16"}, {"@count": "1", "@label": "2010-04-22"}, {"@count": "1", "@label": "2010-05-07"}, {"@count": "1", "@label": "2010-05-21"}, {"@count": "1", "@label": "2010-06-21"}, {"@count": "1", "@label": "2012-11-21"}, {"@count": "1", "@label": "2012-12-04"}, {"@count": "1", "@label": "1996-09-13"}, {"@count": "1", "@label": "2013-02-08"}, {"@count": "1", "@label": "2013-02-13"}, {"@count": "1", "@label": "2013-02-15"}, {"@count": "1", "@label": "2013-03-26"}, {"@count": "1", "@label": "2013-04-04"}, {"@count": "1", "@label": "2013-04-08"}, {"@count": "1", "@label": "2013-04-10"}, {"@count": "1", "@label": "2013-05-16"}, {"@count": "1", "@label": "2013-05-23"}, {"@count": "1", "@label": "2013-05-27"}, {"@count": "1", "@label": "2013-07-01"}, {"@count": "1", "@label": "2013-07-12"}, {"@count": "1", "@label": "2013-07-29"}, {"@count": "1", "@label": "2013-08-02"}, {"@count": "1", "@label": "1996-04-25"}, {"@count": "1", "@label": "2013-09-16"}, {"@count": "1", "@label": "1996-03-12"}, {"@count": "1", "@label": "2013-11-07"}, {"@count": "1", "@label": "2013-12-04"}, {"@count": "1", "@label": "2014-05-12"}, {"@count": "1", "@label": "2011-06-30"}, {"@count": "1", "@label": "2011-07-06"}, {"@count": "1", "@label": "2011-07-13"}, {"@count": "1", "@label": "1996-10-16"}, {"@count": "1", "@label": "2011-07-15"}, {"@count": "1", "@label": "2011-08-08"}, {"@count": "1", "@label": "2011-08-11"}, {"@count": "1", "@label": "2011-08-15"}, {"@count": "1", "@label": "2011-08-30"}, {"@count": "1", "@label": "2011-09-22"}, {"@count": "1", "@label": "2011-11-22"}]}, {"@total": "10", "@label": "Highest Phase", "@name": "phaseHighest", "FilterOption": [{"@id": "DR", "@count": "69", "@label": "Discovery"}, {"@id": "NDR", "@count": "50", "@label": "No Development Reported"}, {"@id": "L", "@count": "33", "@label": "Launched"}, {"@id": "C1", "@count": "30", "@label": "Phase 1 Clinical"}, {"@id": "DX", "@count": "24", "@label": "Discontinued"}, {"@id": "C2", "@count": "15", "@label": "Phase 2 Clinical"}, {"@id": "C3", "@count": "11", "@label": "Phase 3 Clinical"}, {"@id": "PR", "@count": "4", "@label": "Pre-registration"}, {"@id": "R", "@count": "3", "@label": "Registered"}, {"@id": "S", "@count": "2", "@label": "Suspended"}]}, {"@total": "8", "@label": "Drug Deals Count", "@name": "drugDealsCount", "FilterOption": [{"@count": "83", "@label": "= 0"}, {"@count": "59", "@label": "> 1 and \u2264 1"}, {"@count": "25", "@label": "> 2 and \u2264 2"}, {"@count": "28", "@label": "> 3 and \u2264 3"}, {"@count": "14", "@label": "> 4 and \u2264 4"}, {"@count": "8", "@label": "> 5 and \u2264 5"}, {"@count": "22", "@label": "> 6 and \u2264 10"}, {"@count": "2", "@label": "> 11"}]}, {"@total": "5", "@label": "Drug Sales 2010 (USD M)", "@name": "drugSalesYearActual", "FilterOption": [{"@count": "7", "@label": "< 100"}, {"@count": "4", "@label": "\u2265 100 and  250"}, {"@count": "1", "@label": "\u2265 250 and  500"}, {"@count": "6", "@label": "\u2265 500 and  1000"}, {"@count": "4", "@label": "\u2265 1000"}]}, {"@total": "2", "@label": "Drug Has Financials", "@name": "drugHasFinancials", "FilterOption": [{"@count": "214", "@label": "No"}, {"@count": "27", "@label": "Yes"}]}]}, "SearchResults": {"Drug": [{"CompanyOriginator": "Protiva Biotherapeutics Inc", "CompaniesSecondary": {"Company": "Protiva Biotherapeutics Inc"}, "@name": "TKM-Ebola", "AddedDate": "2007-06-01T00:00:00Z", "Summary": "...technology (formerly stabilized nucleic acid lipid particles (SNALP) delivery system), as TKM-<b>Ebola</b> (TKM-100201; Pro-EBOV, TKM-100802), which target an undisclosed filovirus gene for the potential iv treatment of <b>Ebola</b> [800942], [800962], [912282], [1139251], [1480966], [1519299]. In January 2012, a phase I...In December 2013, the company received clearance for its more potent formulation of TKM-<b>Ebola</b> and planned to receive IRB approval. At that time, subject enrollment was planned in early...", "@phaseHighest": "Phase 1 Clinical", "CompaniesPrimary": {"Company": "Tekmira Pharmaceuticals Corp"}, "Technologies": {"Technology": ["Biological therapeutic", "Intravenous formulation", "Liposome formulation", "Oligonucleotide"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "57447", "@lastModificationDate": "2014-03-06T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target", "siRNA agent"]}}, {"CompanyOriginator": "Crucell NV", "CompaniesSecondary": {"Company": "Crucell NV"}, "@name": "Ebola virus vaccine (recombinant adenoviral vector vaccine), Crucell/NIAID", "AddedDate": "2002-05-17T00:00:00Z", "Summary": "...recombinant adenovirus serotype 5 (rAd5) vectors, one encoding glycoprotein from the Zaire strain of <b>Ebola</b> and one encoding glycoprotein from the Sudan-Gulu strain, for the potential prevention of <b>Ebola</b> virus infection. In September 2006, a phase I trial was initiated [694079]; by May 2009, the trial...recombinant adenovirus serotype 5 (rAd5) vectors, one encoding glycoprotein from the Zaire strain of <b>Ebola</b> and one encoding glycoprotein from the Sudan-Gulu strain, and produced in Crucell's human PER.C6...", "@phaseHighest": "Phase 1 Clinical", "CompaniesPrimary": {"Company": ["National Institute of Allergy and Infectious Diseases", "National Institutes of Health"]}, "Technologies": {"Technology": ["Biological therapeutic", "Intramuscular formulation", "Virus recombinant"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "39729", "@lastModificationDate": "2013-05-20T00:00:00Z", "ActionsSecondary": {"Action": ["Prophylactic vaccine", "Recombinant viral vector vaccine"]}}, {"CompanyOriginator": "National Institute of Allergy and Infectious Diseases", "AddedDate": "2010-05-21T00:00:00Z", "@name": "nucleic acid vaccine (Ebola virus infection), NIAID", "Summary": "...Diseases (NIAID) is investigating a vaccine comprising nucleic acid molecules encoding <b>Ebola</b> viral proteins including glycoproteins, from Zaire, Sudan, Ivory Coast, Reston strains and the genetically related Marburg virus strains, for the potential prevention of <b>Ebola</b> virus infection. In May 2002, preclinical development was ongoing; in March 2013...glycoproteins from the Zaire and the Sudan/Gulu strains, for the potential im prevention of <b>Ebola</b> virus infection, ultimately as part of a prime-boost vaccine regimen that may also...", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": ["National Institute of Allergy and Infectious Diseases", "National Institutes of Health"]}, "Technologies": {"Technology": ["Biological therapeutic", "Intramuscular formulation", "Virus recombinant"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "66572", "@lastModificationDate": "2013-05-30T00:00:00Z", "ActionsSecondary": {"Action": ["DNA vaccine", "Nucleic acid vaccine", "Prophylactic vaccine", "Recombinant viral vector vaccine"]}}, {"CompanyOriginator": "NanoViricides Inc", "AddedDate": "2008-02-20T00:00:00Z", "@name": "Ebola and Dengue virus therapy (nanoparticle formulation), NanoViricides/US Army Medical Research Institute of Infectious Diseases", "Summary": "...polymer, for the potential treatment of viral hemorrhagic fevers, including fevers caused by <b>Ebola</b> and Dengue viruses [845359], [1075467], [1149656], [1202559], [1468593]. In February 2008, positive in vitro <b>Ebola</b> data were reported [877871]; in February 2011, positive in vitro and in vivo Dengue data were presented [1169976]. In March 2012, efficacy studies in animals were ongoing for Dengue and <b>Ebola</b> virus infections [1273833], [1268590]. In September 2013, the company intended to initiate...", "IndicationsSecondary": {"Indication": "Viral infection"}, "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": ["NanoViricides Inc", "US Army Medical Research Institute of Infectious Diseases"]}, "Technologies": {"Technology": ["Nanoparticle formulation", "PEGylated formulation", "Small molecule therapeutic"]}, "IndicationsPrimary": {"Indication": ["Dengue virus infection", "Ebola virus infection"]}, "@id": "59524", "@lastModificationDate": "2014-01-15T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}, {"CompanyOriginator": "Prosetta Antiviral Inc", "AddedDate": "2011-07-14T00:00:00Z", "@name": "viral capsid assembly inhibitors (influenza/Ebola virus infections), Prosetta", "Summary": "...viral capsid assembly inhibitors including PAV-667, for the potential treatment of <b>Ebola</b> and influenza virus infections. By April 2010, SAR work had been ongoing with animal...outlicense its programs [1395930], [1395951].The company is also investigating PAV-617 for <b>Ebola</b>, HCV, VEEV infections and the other series of viral capsid assembly inhibitors for...microM, 0.10 microM, 0.10 microM and 10, respectively [1092244], [1094352], [1094433].<b>Ebola</b> virusIn April 2010, preclinical data were presented at the 23rd International Conference...", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Prosetta Antiviral Inc"}, "Technologies": {"Technology": "Small molecule therapeutic"}, "IndicationsPrimary": {"Indication": ["Ebola virus infection", "Influenza virus infection"]}, "@id": "72495", "@lastModificationDate": "2014-04-09T00:00:00Z", "ActionsSecondary": {"Action": ["Unspecified drug target", "Viral replication inhibitor"]}}, {"CompanyOriginator": "University of Iowa", "AddedDate": "2013-08-02T00:00:00Z", "@name": "ARD-5 (ebola virus infection), University of Iowa", "Summary": "University of Iowa is investigating ARD-5, an antibody against VH/VL domain of T cell immunoglobulin and mucin domain (TIM)-1 for the potential treatment of <b>Ebola</b> virus infection. In July 2013, development was ongoing and at that time, the university was seeking to outlicense the antibody [1454998].By July 2013, data had shown that ARD-5 blocked <b>Ebola</b> virus binding and limited the virus infectivity to similar levels as removal of the receptor from the cell surface [1454998].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "University of Iowa"}, "Technologies": {"Technology": ["Antibody", "Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "86676", "@lastModificationDate": "2013-08-02T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}, {"CompanyOriginator": "Harvard University", "AddedDate": "2013-07-29T00:00:00Z", "@name": "small molecule ebola virus entry inhibitors, Harvard University/Harvard University Office of Technology Development", "Summary": "Harvard University is investigating small molecule inhibitors of <b>ebola</b> virus (EboV) entry, for the potential treatment of <b>ebola</b> virus infection. In February 2012, development was underway [1455804], [1457347], [1457373]; in July 2013, this was still the case and at that time...of the EboV inhibitor (3.0), was found to be more potent inhibitor of the Lassa fever virus. An additional compound (7) inhibited Lassa fever and <b>Ebola</b> virus infection equally well [1455804], [1457347], [1457373].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": ["Harvard University", "Harvard University Office of Technology Development"]}, "Technologies": {"Technology": "Small molecule therapeutic"}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "86603", "@lastModificationDate": "2013-07-29T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}, {"CompanyOriginator": "AlphaVax Inc", "AddedDate": "2006-04-08T00:00:00Z", "@name": "recombinant viral vector vaccine (ArV, VEE virus technology, filovirus/Marburg/Ebola virus infection), AlphaVax", "Summary": "...system, for the potential treatment of filovirus infection inlcuding Marburg and <b>Ebola</b> virus infection [506839], [645889], [1070226]. In January 2010, GMP-compliant clinical...filovirus vaccine. At that time, development of a multivalent vaccine against Marburg and <b>Ebola</b> into clinical trials was being reviewed [1070226]. In May 2013, the vaccine was still...alphavirus replicon particle vaccines expressing glycoprotein from either the Marburg or <b>Ebola</b> viruses protected non-human primates against lethal challenge with Marburg or <b>Ebola</b>...", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "AlphaVax Inc"}, "Technologies": {"Technology": ["Biological therapeutic", "Parenteral formulation unspecified", "Virus recombinant"]}, "IndicationsPrimary": {"Indication": ["Ebola virus infection", "Filovirus infection", "Marburg virus infection"]}, "@id": "55209", "@lastModificationDate": "2013-05-21T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Recombinant viral vector vaccine", "Therapeutic vaccine"]}}, {"CompanyOriginator": "US Army Medical Research Institute of Infectious Diseases", "AddedDate": "2013-04-10T00:00:00Z", "@name": "filoGP-Fc fusion protein subunit vaccine (ebola virus infection), USAMRIID", "Summary": "...of flio virus glycoprotein (gp) fused to a Fc fragment of human immunoglobulin (filoGp-Fc), for the potential prevention of <b>ebola</b> virus infection [1400816]. In August 2012, preclinical development was ongoing. At that time, NIH Office of Technology Transfer was seeking to outlicense the program [1395222].In April 2011, preclinical data were published. Mice immunized with zaire <b>ebola</b> virus (ZEBOV) gp fused to the Fc fragment of human IgG1 (ZEBOVGP-Fc) developed T-cell immunity against ZEBOV gp and neutralizing...", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": ["National Institutes of Health", "US Army Medical Research Institute of Infectious Diseases"]}, "Technologies": {"Technology": ["Antibody fragment", "Biological therapeutic", "Protein fusion", "Virus recombinant"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "84338", "@lastModificationDate": "2013-05-07T00:00:00Z", "ActionsSecondary": {"Action": ["Prophylactic vaccine", "Protein subunit vaccine", "Recombinant viral vector vaccine"]}}, {"CompanyOriginator": "Greffex Inc", "AddedDate": "2014-05-12T00:00:00Z", "@name": "ebola virus vaccine, Greffex", "Summary": "Greffex is investigating a vaccine developed using its GREVAX platform of engineered adenovirus vector as nanoparticle formulation, for the potential prevention or treatment of <b>ebola</b> virus infection [1554539], [1553642], [1554425]. In May 2014, development was ongoing [1554425].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Greffex Inc"}, "Technologies": {"Technology": ["Biological therapeutic", "Nanoparticle formulation"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "91170", "@lastModificationDate": "2014-05-12T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Recombinant viral vector vaccine"]}}, {"CompanyOriginator": "SKAU Vaccines ApS", "AddedDate": "2013-02-08T00:00:00Z", "@name": "Ebola vaccine, SKAU Vaccines", "Summary": "SKAU Vaccines is investigating a vaccine, based on the company's proprietary Hyper Immunogenic Antigen (HIA) technology, for the potential prevention or treatment of <b>Ebola</b> infection. In February 2013, the vaccine was in preclinical development. At that time, the company was seeking to outlicense the vaccine [1368512].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "SKAU Vaccines ApS"}, "Technologies": {"Technology": ["Antigen", "Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "83252", "@lastModificationDate": "2013-02-20T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified vaccine"]}}, {"CompanyOriginator": "Profectus BioSciences Inc", "AddedDate": "2011-09-22T00:00:00Z", "@name": "rVSV Ebola/Marburg vaccine, Profectus BioSciences", "Summary": "...G-proteins, developed using the company's vesiculovirus\u2010vectored vaccine delivery platform, for the potential treatment of <b>Ebola</b> and Marburg viruses [1224706], [1286555], [1480508]. In January 2014, preclinical development was ongoing [1515084].In September...EboV and MarV infections [1514939]. By September 2011, preclinical studies had showed that a single injection of the rVSV-<b>Ebola</b> vaccine protected guinea pigs and rhesus macaques against the Zaire strain of <b>Ebola</b> virus [1224706].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Profectus BioSciences Inc"}, "Technologies": {"Technology": ["Biological therapeutic", "Vector expression", "Virus recombinant"]}, "IndicationsPrimary": {"Indication": ["Ebola virus infection", "Marburg virus infection"]}, "@id": "73662", "@lastModificationDate": "2014-01-16T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Immunomodulator", "Live attenuated viral vaccine", "Protein subunit vaccine", "Recombinant viral vector vaccine"]}}, {"CompanyOriginator": "Microbiotix Inc", "AddedDate": "2010-07-19T00:00:00Z", "@name": "Ebola virus entry inhibitors, Microbiotix", "Summary": "...small molecules that inhibit viral entry for the potential treatment or prevention of <b>Ebola</b> virus infection [1116744], [1394538]. By July 2009, screening was underway [1117135...2012, the company was planning to evaluate the compounds in a guinea pig model of <b>Ebola</b> virus infection [1394538].By July 2009, approximately 52,500 compounds had been screened for viral entry inhibition activity. Eight compounds inhibited <b>Ebola</b> virus infection with IC50 values below 20 microM [1117135]. In July 2010, further...", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Microbiotix Inc"}, "Technologies": {"Technology": "Small molecule therapeutic"}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "67398", "@lastModificationDate": "2013-03-22T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}, {"CompanyOriginator": "Prosetta Antiviral Inc", "AddedDate": "2011-07-14T00:00:00Z", "@name": "viral capsid assembly inhibitors (HCV/Ebola/VEEV infection), Prosetta", "Summary": "...of viral capsid assembly inhibitors, for the potential treatment of hepatitis C, <b>Ebola</b> and Venezuelan equine encephalitis virus (VEEV) infections. By April 2010, SAR work...of viral capsid assembly inhibitors, for the potential treatment of hepatitis C, <b>Ebola</b> and Venezuelan equine encephalitis virus (VEEV) infections. By April 2010, SAR work...studies expected soon [1092410], [1094352], [1094433], [1091578], [1091792], [1092352]. <b>Ebola</b> virusIn April 2010, preclinical data were presented at the 23rd International Conference...", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Prosetta Antiviral Inc"}, "Technologies": {"Technology": "Small molecule therapeutic"}, "IndicationsPrimary": {"Indication": ["Ebola virus infection", "Hepatitis C virus infection", "Venezuelan equine encephalitis virus infection"]}, "@id": "72484", "@lastModificationDate": "2014-04-09T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}, {"CompanyOriginator": "US Army Medical Research and Materiel Command", "AddedDate": "2013-07-12T00:00:00Z", "@name": "antibody vaccine (ebola virus infection), US Army Medical Research and Materiel Command", "Summary": "The US Army Medical Research and Materiel Command is investigating an antibody vaccine, which binds to the virus and inhibits it from spreading, for the potential prevention and treatment of <b>Ebola</b> virus infection. In July 2010, the agency was seeking to outlicense the program [1451538].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "US Army Medical Research and Materiel Command"}, "Technologies": {"Technology": ["Antibody", "Biological therapeutic", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "86287", "@lastModificationDate": "2013-07-18T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Prophylactic vaccine", "Therapeutic vaccine"]}}, {"CompanyOriginator": "Navigen Inc", "AddedDate": "2013-04-04T00:00:00Z", "@name": "trimeric non-degradable protease-resistant D-peptide program (ebola virus infection), Navigen", "Summary": "Navigen Pharmaceuticals, is investigating a trimeric non-degradable protease-resistant D-peptides found on <b>ebola</b> viral surface, for the potential prevention of <b>ebola</b> virus. In June 2012, development of the program was ongoing [1394704]; in September 2013, this was still the case [1478837].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Navigen Inc"}, "Technologies": {"Technology": ["Biological therapeutic", "Parenteral formulation unspecified", "Peptide"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "84042", "@lastModificationDate": "2013-09-19T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}, {"CompanyOriginator": "Scripps Research Institute", "AddedDate": "2011-11-23T00:00:00Z", "@name": "neutralizing antibody (Ebola virus infection), Scripps/USAMRIID", "Summary": "The Scripps Research Institute and the US Army Medical Research Institute of Infectious Diseases (USAMRIID) are investigating the antibody 16F6 for the potential treatment of <b>Ebola</b>-Sudan virus infection [1241883], [1242175].In November 2011, data were published showing that the antibody neutralized Sudan virus in vitro and also significantly delayed death in mice infected with the virus [1241883], [1242175].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": ["Scripps Research Institute", "US Army Medical Research Institute of Infectious Diseases"]}, "Technologies": {"Technology": ["Antibody", "Biological therapeutic"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "74634", "@lastModificationDate": "2013-05-28T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}, {"CompanyOriginator": "Okairos", "AddedDate": "2009-05-26T00:00:00Z", "@name": "vaccine (Marburg/Ebola virus infection), Okairos", "Summary": "Okairos, a subsidiary of GlaxoSmithKline, is investigating a vaccine for the potential treatment or prevention of <b>Ebola</b> virus infection [1012432], [1430235]. By April 2009, preclinical studies were ongoing [1012432]. In June 2012, the vaccine was listed as being under preclinical development [1302855]. In May 2013, this was still the case [1430880].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Okairos"}, "Technologies": {"Technology": "Biological therapeutic"}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "63473", "@lastModificationDate": "2013-05-30T00:00:00Z", "ActionsSecondary": {"Action": "Vaccine"}}, {"CompanyOriginator": "Vaxart Inc", "AddedDate": "2013-03-26T00:00:00Z", "@name": "adenovirus vector 5-based ebola vaccine (oral/tablet), Vaxart", "Summary": "Vaxart is investigating an oral tablet formulation of non-replicating adenovirus vector type 5-based vaccine, for the potential treatment or prevention of <b>Ebola</b> virus infection. In January 2013, the vaccine was listed as being in immunogenicity studies [1394706].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Vaxart Inc"}, "Technologies": {"Technology": ["Biological therapeutic", "Oral formulation", "Tablet formulation", "Virus recombinant"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "84041", "@lastModificationDate": "2013-03-27T00:00:00Z", "ActionsSecondary": {"Action": "Recombinant viral vector vaccine"}}, {"CompanyOriginator": "Humabs BioMed SA", "AddedDate": "2012-04-20T00:00:00Z", "@name": "fully human monoclonal antibody therapy (ebola virus infection), Humabs BioMed", "Summary": "Humabs BioMed is investigating fully human mAbs for the potential treatment of <b>Ebola</b> virus infection. In April 2012, the antibodies were listed as being in preclinical development [1280479]; in January 2014, this was still the case [1516284]. In April 2012, the company was seeking to outlicense the antibodies [1280479]; in January 2014, this was still the case [1516284].", "@phaseHighest": "Discovery", "CompaniesPrimary": {"Company": "Humabs BioMed SA"}, "Technologies": {"Technology": ["Biological therapeutic", "Monoclonal antibody human", "Parenteral formulation unspecified"]}, "IndicationsPrimary": {"Indication": "Ebola virus infection"}, "@id": "77313", "@lastModificationDate": "2014-01-17T00:00:00Z", "ActionsSecondary": {"Action": ["Antiviral", "Unspecified drug target"]}}]}, "@hits": "20", "@totalResults": "241", "@offset": "0"}}